[go: up one dir, main page]

MX2016016281A - Polipeptidos receptores formulados y metodos relacionados. - Google Patents

Polipeptidos receptores formulados y metodos relacionados.

Info

Publication number
MX2016016281A
MX2016016281A MX2016016281A MX2016016281A MX2016016281A MX 2016016281 A MX2016016281 A MX 2016016281A MX 2016016281 A MX2016016281 A MX 2016016281A MX 2016016281 A MX2016016281 A MX 2016016281A MX 2016016281 A MX2016016281 A MX 2016016281A
Authority
MX
Mexico
Prior art keywords
related methods
formulated
receptor polypeptides
disclosed
methods
Prior art date
Application number
MX2016016281A
Other languages
English (en)
Inventor
Michael Haqq Christopher
Latypov Ramil
Original Assignee
Santa Maria Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of MX2016016281A publication Critical patent/MX2016016281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se revela en la presente una composición a base de un receptor de activina lIB y métodos de uso relacionados, por ejemplo, para tratar tumores sólidos. También se revelan métodos de preparación del compuesto y la formulación.
MX2016016281A 2014-06-13 2015-06-15 Polipeptidos receptores formulados y metodos relacionados. MX2016016281A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462012104P 2014-06-13 2014-06-13
US201462047995P 2014-09-09 2014-09-09
US201462058789P 2014-10-02 2014-10-02
US201562142812P 2015-04-03 2015-04-03
PCT/US2015/035818 WO2015192127A2 (en) 2014-06-13 2015-06-15 Formulated receptor polypeptides and related methods

Publications (1)

Publication Number Publication Date
MX2016016281A true MX2016016281A (es) 2017-03-31

Family

ID=54834575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016281A MX2016016281A (es) 2014-06-13 2015-06-15 Polipeptidos receptores formulados y metodos relacionados.

Country Status (19)

Country Link
US (2) US20170202909A1 (es)
EP (1) EP3155008B1 (es)
JP (1) JP2017519009A (es)
KR (1) KR20170035891A (es)
CN (1) CN107074931A (es)
AP (1) AP2016009647A0 (es)
AU (1) AU2015274293A1 (es)
BR (1) BR112016029211A2 (es)
CA (1) CA2952231A1 (es)
CL (1) CL2016003191A1 (es)
EA (1) EA201692568A1 (es)
IL (1) IL249373A0 (es)
MX (1) MX2016016281A (es)
PE (1) PE20170471A1 (es)
PH (1) PH12016502479A1 (es)
SG (1) SG11201610432UA (es)
TN (1) TN2016000551A1 (es)
TW (1) TW201625675A (es)
WO (1) WO2015192127A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101526613B1 (ko) 2007-02-01 2015-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
DK3494986T3 (da) 2008-08-14 2020-08-03 Acceleron Pharma Inc GDF fanger
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010144452A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX2011013364A (es) 2009-06-12 2012-03-16 Acceleron Pharma Inc Proteinas de fusion actriib-fc truncadas.
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
HK1218553A1 (zh) 2013-02-01 2017-02-24 Santa Maria Biotherapeutics, Inc. 抗激活素a化合物對受試者的施用
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
WO2016171948A1 (en) 2015-04-22 2016-10-27 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
KR20180128405A (ko) * 2016-02-22 2018-12-03 악셀레론 파마 인코포레이티드 면역 활성 증가에 사용하기 위한 ActRII 길항제
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
AU2017357935B2 (en) 2016-11-10 2022-04-28 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
KR102655498B1 (ko) * 2017-09-07 2024-04-11 제이씨알 파마 가부시키가이샤 수성 의약 조성물
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL275936B1 (en) 2018-01-12 2025-05-01 Keros Therapeutics Inc Activin receptor type IIB variants and methods of using them
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
US11357726B2 (en) * 2018-08-29 2022-06-14 Translate Bio, Inc. Process of preparing mRNA-loaded lipid nanoparticles
KR20210102874A (ko) * 2018-10-12 2021-08-20 어드밴스드 액셀러레이터 어플리케이션즈 인터내셔널 에스.에이. 방사성 표지된 gprp 길항제 및 계면활성제를 포함하는 약학적 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
EP1129190B2 (en) 1998-11-13 2017-01-11 Immunex Corporation Human tslp dna and polypeptides
JP4038118B2 (ja) 2002-11-29 2008-01-23 株式会社コガネイ 流体圧シリンダ
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TW201718635A (zh) * 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
KR101720143B1 (ko) * 2008-11-26 2017-03-27 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
HK1218553A1 (zh) * 2013-02-01 2017-02-24 Santa Maria Biotherapeutics, Inc. 抗激活素a化合物對受試者的施用
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins

Also Published As

Publication number Publication date
WO2015192127A2 (en) 2015-12-17
PE20170471A1 (es) 2017-05-14
CN107074931A (zh) 2017-08-18
US20170202909A1 (en) 2017-07-20
SG11201610432UA (en) 2017-01-27
AU2015274293A1 (en) 2017-02-02
AP2016009647A0 (en) 2016-12-31
TN2016000551A1 (en) 2018-04-04
TW201625675A (zh) 2016-07-16
BR112016029211A2 (pt) 2018-01-30
PH12016502479A1 (en) 2017-04-10
JP2017519009A (ja) 2017-07-13
KR20170035891A (ko) 2017-03-31
CL2016003191A1 (es) 2017-11-10
IL249373A0 (en) 2017-02-28
EA201692568A1 (ru) 2017-05-31
EP3155008A4 (en) 2018-05-16
CA2952231A1 (en) 2015-12-17
US20240277805A1 (en) 2024-08-22
WO2015192127A3 (en) 2016-03-17
EP3155008A2 (en) 2017-04-19
EP3155008B1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
MY192927A (en) Fused bicyclic compounds for the treatment of disease
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
IN2014CH00304A (es)
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
NZ721832A (en) Solid forms of tenofovir
HK1236549A1 (en) Formulated receptor polypeptides and related methods
EA201692453A1 (ru) Способ получения ингаляционных составов